Skip to content

Ginkgo Bioworks DNA Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

ClearPoint Neuro logo
ClearPoint NeuroCLPT
$5.39M-39.4%
Twist Bioscience Corporation logo
Twist Bioscience CorporationTWST
$24.8M+9.5%
Guardant Health logo
Guardant HealthGH

Other financials

Income statement

See full
Revenue$19.5M-49.1%
Gross profit$16.4M-52.0%
Operating income-$71.4M+11.9%
Net income-$82.6M+9.2%
EPS (diluted)-$1.42+27.6%

Balance sheet

See full
Cash & equivalents$188.7M-46.9%
Total debt$410.7M-5.5%
Total equity$443.2M-31.6%
Total assets$1.0B-20.1%

Cash flow

See full
Operating cash flow-$46.7M+9.4%
CapEx$1.9M-74.6%
Free cash flow-$48.6M+17.8%

Valuation

See full
Market cap$625.16M+24.6%
Enterprise value$847.19M+45.9%
P/S4.4×+2.2×

Profitability

See full
Operating margin-210.7%+7.6pp
Net margin-215.4%+8.3pp
FCF margin-119%-21.2pp

Returns & leverage

See full
Return on equity-55.8%-1.8pp
Debt / equity0.9×+0.3×
Current ratio5.2×+0.3×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ginkgo Bioworks's common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ginkgo Bioworks's common stock shares outstanding?
Ginkgo Bioworks (DNA) reported common stock shares outstanding of $0 in Q1 2026.
What does common stock shares outstanding mean?
This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.